Vaccines in the 21st century

Infectious Disease Clinics of North America

Volumn 15, Issue 1, 2001, Pages 307-327

  Plotkin, Stanley A ^b  

^a Aventis Pasteur   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CHICKENPOX VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; MEASLES MUMPS RUBELLA VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; VIRUS VACCINE;

BACTERIAL INFECTION; CLINICAL PROTOCOL; DEVELOPING COUNTRY; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MATERNAL CARE; NEWBORN INFECTION; PREGNANCY; REVIEW; RUSSIAN FEDERATION; UNITED STATES; VACCINATION; VIRUS INFECTION;

EID: 0035057276     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70280-4     Document Type: Article

References (110)

1. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)
2. Novel adjuvants currently in clinical testing
3. Immune responses in humans and animals to meningococcal transferrin-binding proteins: Implications for vaccine design
4. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis
5. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's path M cells
6. The promise of proteomics
7. Withdrawal of rotavirus vaccine recommendations
8. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigen
9. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus
10. Protection against mycoplasma infection using expression-library immunization
11. Immunological memory to HIB following combined acellular pertussis diphtheria, tetanus/HIB vaccine
12. Influenza vaccine: Is it time for universal immunization
13. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
14. Immunization with a live attenuated dengue-2 virus candidate vaccine (16681-PDK 53): Clinical immunologic-val and biological responses in adult volunteers
15. Efficacy, safety, and immunogenicity of heptavalent conjugate pneumococcal vaccine in children
16. Proteomics: Quantitative and physical mapping of cellular proteins
17. Insertion of the fusion gene from New-castle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant
18. Development of dengue and Japanese encephalitis vaccines
19. Exploring the new world of the genome with DNA micro-arrays
20. Immunisation with canarypox virus expressing rabies glycoprotein
21. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
22. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line
23. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins
24. Rotavirus vaccines
25. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp 120, HIV-1SF2 recombinant gp 120, or both vaccines in seronegative adults
26. Rotavirus vaccine administered parenterally induces protective immunity
27. Induction and assessment of immunity at enteromucosal surfaces in humans: Implications for vaccine development
28. Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization
29. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants
30. Interventions for the control of diarrhoeal diseases among young children: Rotavirus and cholera immunization
31. Combination vaccines
32. Respiratory syncytial virus vaccines
33. Pertussis vaccine
34. New technologies for making vaccines
35. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp 120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
36. Safety and immunogenicity of a fully liquid combination vaccine, with acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilis influenzae serotype b, and hepatitis B when given in infants at 2, 3, and 4 months of age
37. Immunogenicity of the fourth dose of a hexavalent, fully liquid, acellular pertussis combination vaccine given to infants at 12 and 14 months of age
38. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis
39. Prevention of type 1 diabetes from laboratory to public health
40. Specific immune response in humans following rectal delivery of live typhoid vaccine
41. Efficacy of a therapeutic cocaine vaccine in rodent models
42. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
43. Adult immunization: Principles and practice
44. Varicella vaccine
45. A canarypox vector expressing cytomegalovirus phosphoprotein 65 induces longlasting cytotoxic T cell responses in HCMV seronegative volunteers
46. Report of a workshop: Immunization of pregnant women
47. Oral immunization with a recombinant bacterial antigen produced in transgenic plants
48. Smallpox and vaccinia
49. Herpes simplex virus turns off the TAP to evade host immunity
50. Toward HIV eradication or remission: The tasks ahead
51. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV
52. The prevention of type 1 diabetes mellitus
53. Inactivated influenza vaccines
54. A highly attenuated host-range restricted vaccinia virus strain, NYVAC, encoding the prM, E and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine
55. The outer surface protein A (OspA) of Borrelia burgdorferi: A vaccine candidate and bioactive mediator
56. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
57. Progress in the development of an HIV-1 vaccine
58. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine
59. Pathogenesis of human immunodeficiency virus infection
60. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines
61. Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases
62. New perspectives in mucosal immunity with emphasis on vaccine development
63. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
64. Immunization against rabies with plant-derived antigen
65. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
66. Vaccinia virus vectors
67. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: A randomized controlled trial
68. Phase I/IIa safety, immunogenicity and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
69. Vaccination to prevent persistent viral infection
70. Cancer vaccines
71. Genetically engineered live attenuated influenza A virus vaccine candidates
72. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
73. Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates
74. Poxvirus-based vectors as vaccine candidates
75. The acellular pertussis vaccine trials: An interpretation
76. Acellular vaccine efficacy trials
77. Developed countries should use inactivated polio vaccine for the prevention of poliomyelitis
78. Vaccination against the major infectious diseases
79. Inactivated polio vaccine
80. Vaccination against cytomegalovirus, the changeling demon
81. The development of cowpea mosaic virus as a potential source of novel vaccines
82. Active immunization with pC protein of Borrelia burgdorferi protects gerbils against B. burgdorferi infection
83. Propagation of human hepatitis A virus in cell culture in vitro
84. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - Report of the National Multicenter Trial
85. Nucleic acid vaccines: An overview
86. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
87. Challenges for vaccination against sexually-transmitted diseases: Induction and long-term maintenance of mucosal immune responses in the female genital tract
88. Alphaviruses - Vectors for the expression of heterologous genes
89. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations
90. Preparation characterization, and immunogenicity of H. influenza type b polysaccharide-protein conjugates
91. Vaccines for bacterial sexually transmitted infections: A realistic goal?
92. Herpes simplex virus vaccines as immunotherapeutic agents
93. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant
94. Immunization of Macaca mulatta with aroA attenuated Salmonella typhimurium expressing the SIVp27 antigen
95. Live attenuated poliovirus vaccines
96. Vaccines for control of fertility and hormone-dependent cancers
97. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria
98. Immunogenicity of transgenic plant-derived hepatitis B surface antigen
99. Alphavirus expression vectors and their use as recombinant vaccines: A minireview
100. A trial of a group A plus group C meningococ meningococcal polysaccharide-protein conjugate vaccine in African infants
101. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
102. Pediatric combination vaccines
103. Induction of antigen-specific cytotoxic T meningococ meningococcytes in humans by a malaria DNA vaccine
104. Haemophilus influenza vaccines
105. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines
106. Adhesins as targets for vaccine development
107. Direct gene transfer into mouse muscle in vivo
108. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: Plain Haemophilus influenzae type b-PRP (Hib) boosters in children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine
109. Self-replicating Semliki Forest virus RNA as recombinant vaccine